“A General Revolt in the Name of the Soul”: The Mind-Cure and Psychotherapeutic Movements in America

The incipient therapeutic movements of the late-Victorian and Progressive eras in the US are salient to understanding the ways in which the desire to heal and be healed has at once a subtle and far-reaching influence on how crisis is understood and social transformation is carried out. Historians of late have amply documented how lay, faith, and medical healers of these eras negotiated new forms of selfhood amidst a rapidly changing political and socioeconomic order. Yet the historical portrait remains incomplete insofar as critical examination has not been paid to the “crisis resolution” specific to this reformation: the optimistic healing narrative that the sociomedical discourse on nervous diseases engendered. Such an investigation into this veritable birth of the therapeutic helps disclose how a dominant set of psychosomatic interpretations and healing modalities could cohere alongside both the evolving structure of monopoly capitalism and the designated roles people assumed within it

Space suit

A pressure suit for high altitude flights, particularly space missions is reported. The suit is designed for astronauts in the Apollo space program and may be worn both inside and outside a space vehicle, as well as on the lunar surface. It comprises an integrated assembly of inner comfort liner, intermediate pressure garment, and outer thermal protective garment with removable helmet, and gloves. The pressure garment comprises an inner convoluted sealing bladder and outer fabric restraint to which are attached a plurality of cable restraint assemblies. It provides versitility in combination with improved sealing and increased mobility for internal pressures suitable for life support in the near vacuum of outer space

Test Results from the PF Conductor Insert Coil and Implications for the ITER PF System

In this paper we report the main test results obtained on the Poloidal Field Conductor Insert coil (PFI) for the International Thermonuclear Experimental Reactor (ITER), built jointly by the EU and RF ITER parties, recently installed and tested in the CS Model Coil facility, at JAEA-Naka. During the test we (a) verified the DC and AC operating margin of the NbTi Cable-in-Conduit Conductor in conditions representative of the operation of the ITER PF coils, (b) measured the intermediate conductor joint resistance, margin and loss, and (c) measured the AC loss of the conductor and its changes once subjected to a significant number of Lorentz force cycles. We compare the results obtained to expectations from strand and cable characterization, which were studied extensively earlier. We finally discuss the implications for the ITER PF system

Lessons from the Pivot: Higher Education\u27s Response to the Pandemic

This text includes chapters from instructional designers, university faculty and staff, and undergraduate and graduate students, and the text has been divided into three sections to reflect these varied perspectives. Each section begins with research-based perspectives, but also contains more personal narratives at the end. While the context of most of the chapters is the United States, there are also chapters with a Canadian context. It is also important to note that, as of the first half of 2021, the pandemic rages on, and mentions of COVID-19 in the following chapters will be reflective of the state of affairs in North America in the spring and fall of 2020.https://scholar.umw.edu/education_books/1000/thumbnail.jp

Optimisation of ITER Nb3Sn CICCs for coupling loss, transverse electromagnetic load and axial thermal contraction

The ITER cable-in-conduit conductors (CICCs) are built up from sub-cable bundles, wound in different stages, which are twisted to counter coupling loss caused by time-changing external magnet fields. The selection of the twist pitch lengths has major implications for the performance of the cable in the case of strain sensitive superconductors, i.e. Nb3Sn, as the electromagnetic and thermal contraction loads are large but also for the heat load from the AC coupling loss. Reduction of the transverse load and warm-up cool-down degradation can be reached by applying longer twist pitches in a particular sequence for the sub-stages, offering a large cable transverse stiffness, adequate axial flexibility and maximum allowed lateral strand support. Analysis of short sample (TF conductor) data reveals that increasing the twist pitch can lead to a gain of the effective axial compressive strain of more than 0.3 % with practically no degradation from bending. For reduction of the coupling loss, specific choices of the cabling twist sequence are needed with the aim to minimize the area of linked strands and bundles that are coupled and form loops with the applied changing magnetic field, instead of simply avoiding longer pitches. In addition we recommend increasing the wrap coverage of the CS conductor from 50 % to at least 70 %. The models predict significant improvement against strain sensitivity and substantial decrease of the AC coupling loss in Nb3Sn CICCs, but also for NbTi CICCs minimization of the coupling loss can be achieved. Although the success of long pitches to transverse load degradation was already demonstrated, the prediction of the combination with low coupling loss needs to be validated by a short sample test.Comment: to be published in Supercond Sci Techno

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response : efficacy and safety in patients with rheumatoid arthritis

Objectives To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis with non-response or incomplete-response to the initial therapy. Methods SELECT-COMPARE randomised patients to upadacitinib 15 mg once daily (n=651), placebo (n=651) or adalimumab 40 mg every other week (n=327). A treat-to-target study design was implemented, with blinded rescue occurring prior to week 26 for patients who did not achieve at least 20% improvement in both tender and swollen joint counts ('non-responders') and at week 26 based on Clinical Disease Activity Index (CDAI) >10 ('incomplete-responders') without washout. Results A total of 39% (252/651) and 49% (159/327) of patients originally randomised to upadacitinib and adalimumab were rescued to the alternate therapy. In both switch groups (adalimumab to upadacitinib and vice versa) and in non-responders and incomplete-responders, improvements in disease activity were observed at 3 and 6 months following rescue. CDAI low disease activity was achieved by 36% and 47% of non-responders and 45% and 58% of incomplete-responders switched to adalimumab and upadacitinib, respectively, 6 months following switch. Overall, approximately 5% of rescued patients experienced worsening in disease activity at 6 months postswitch. The frequency of adverse events was similar between switch groups. Conclusions These observations support a treat-to-target strategy, in which patients who fail to respond initially (or do not achieve sufficient response) are switched to a therapy with an alternate mechanism of action and experience improved outcomes. No new safety findings were observed despite immediate switch without washout

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

OBJECTIVE: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with newly-diagnosed or recurrent ovarian cancer following a response to platinum-based chemotherapy. We present long-term safety data for niraparib from the ENGOT-OV16/NOVA trial. METHODS: This multicenter, double-blind, randomized, controlled phase III trial evaluated the efficacy and safety of niraparib for the treatment of recurrent ovarian cancer. Patients were randomly assigned 2:1 to receive either once-daily niraparib 300 mg or placebo. Two independent cohorts were enrolled based on germline BRCA mutation status. The primary endpoint was progression-free survival, reported previously. Long-term safety data were from the most recent data cutoff (September 2017). RESULTS: Overall, 367 patients received niraparib 300 mg once daily. Dose reductions due to TEAEs were highest in month 1 (34%) and declined every month thereafter. Incidence of any-grade and grade ≥ 3 hematologic and symptomatic TEAEs was also highest in month 1 and subsequently declined. Incidence of grade ≥ 3 thrombocytopenia decreased from 28% (month 1) to 9% and 5% (months 2 and 3, respectively), with protocol-directed dose interruptions and/or reductions. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) were reported in 2 and 6 niraparib-treated patients, respectively, and in 1 placebo patient each. Treatment discontinuations due to TEAEs were <5% in each month and time interval measured. CONCLUSION: These data demonstrate the importance of appropriate dose reduction according to toxicity criteria and support the safe long-term use of niraparib for maintenance treatment in patients with recurrent ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01847274